The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies, real-world ...

According to Prof Phil Banfield, chair of the BMA council, it had become clear that the centre "no longer has a grip on the ...

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) had been scheduled to meet to discuss the strains ...

Nevertheless, the rise in the Statutory Scheme rate to almost a third of pharma company revenue – which brings the average ...

According to Prof Phil Banfield, chair of BMA council, it had become clear that the centre "no longer has a grip on the ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available. However, as Ben Hargreaves discovers, research ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-Elect has also selected Dave Weldon to lead the Centers for Disease Control and ...

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves. The green light for ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.